Navigation Links
Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302

Third PharmacoSurgery(TM) Platform Product Candidate in Clinical Trials

SEATTLE, Sept. 9 /PRNewswire/ -- Omeros Corporation today announced that it is enrolling patients in a Phase 1/Phase 2 study of OMS302, the Company's third PharmacoSurgery(TM) product candidate, for use during ophthalmologic surgery. At least 60 patients undergoing age-related cataract extraction with lens replacement are planned for enrollment in the study.

"With the initiation of this study, all three of Omeros' current PharmacoSurgery product candidates are now in the clinic," said Gregory A. Demopulos, M.D., Chairman and CEO of Omeros. "Each of the two agents in OMS302 is currently used individually and perioperatively during eye surgery. OMS302 combines these two agents and their pharmacologic activities into a single proprietary product candidate. With approximately three million cataract procedures performed annually in the U.S. alone, OMS302 is designed to address a large and growing market."

The Phase 1/Phase 2 trial is a randomized, double-blind, vehicle-controlled and parallel-assigned study evaluating the effects of OMS302 on dilation of the pupil during cataract surgery and on pain, discomfort and inflammation following the procedure. OMS302 is added to standard irrigation solutions used in ophthalmologic surgery and is delivered directly to the eye during the operation.

PharmacoSurgery(TM) product candidates are proprietary combinations of therapeutic agents designed to act simultaneously at multiple discrete targets to preemptively block the molecular-signaling and biochemical cascade caused by surgical trauma and to provide clinical benefits both during and after surgery. The lead product candidate in the PharmacoSurgery(TM) platform is OMS103HP, which is currently in two Phase 3 clinical programs evaluating its safety and ability to improve postoperative joint function and reduce pain following arthroscopic surgery. The urological PharmacoSurgery(TM) product candidate OMS201, currently in a fully enrolled Phase 1 clinical study, is designed to inhibit surgically induced inflammation, pain and smooth muscle spasm, thereby facilitating uroendoscopy and reducing postoperative frequency, urgency and discomfort.

About Omeros Corporation

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of pre-clinical programs targeting inflammation and central nervous system disorders. For more information on Omeros, visit the Company's Web site at

SOURCE Omeros Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
2. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
3. CVBT Announces First Site to Begin Patient Enrollment for Its Phase II Heart Trial
4. Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients
5. Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
6. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
7. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
8. Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)
9. Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies
10. Morse CyberKnife CEO James G. Schwade, M.D. Announces Non-Surgical Treatment With CyberKnife Radiosurgery for Prostate Cancer
11. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
Post Your Comments:
(Date:11/25/2015)... 2015  The American Academy of Pediatrics (AAP), ... the March of Dimes cheered today,s signature into ... Act of 2015 (S.799), which takes much-needed ... exposed to drugs, such as opioids, and to ... three organizations have worked together leading advocacy efforts ...
(Date:11/25/2015)... -- On Tuesday, November 24, 2015, the jury ... Medical Technology, Inc. for product liability and misrepresentation ... device, awarded $11 million in favor of Plaintiff ... three days of deliberations, the jury found that ... and unreasonably dangerous, and that Wright Medical made ...
(Date:11/25/2015)... Kitov Pharma ceuticals ... biopharmaceutical company focused on the development of therapeutic candidates ... announced the closing of its previously announced underwritten public ... each representing 20 ordinary shares of the Company, and ... and warrants were issued in a fixed combination of ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec Solutions announced ... User Group (MSDSLUG). Recognized as Microsoft’s official group for end users of Dynamics ... software users, partners, industry experts and representatives. Intellitec Solutions’ membership status demonstrates their ...
(Date:11/27/2015)... Minn. (PRWEB) , ... November 27, 2015 , ... ... start failing. Secura Consultants has prided itself for not only fulfilling the needs ... income protection solutions at an affordable price and providing top-tier customer service. However, ...
(Date:11/27/2015)... , ... November 27, 2015 , ... CBD College ... of Allied Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. ... accredited colleges, as only one of twelve colleges and universities in the state of ...
(Date:11/27/2015)... ... ... Dr. Thomas Dunlap and Dr. Patrick Coleman , cardiologist ... Medicine at St., Joseph Health System’s Santa Rosa Memorial Hospital , co-hosted the ... ways and require time-critical intervention to avoid large area heart damage and progressive infections ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., ... the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 ... brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive not ...
Breaking Medicine News(10 mins):